OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards

OBI Pharma, Inc. (4174.TWO), a clinical-stage oncology company, announced that OBI-992, a TROP2 targeted antibody-drug conjugate (ADC), has been shortlisted from over 1,000 nominations submitted as one of the eight “2024 Most Promising Clinical Candidate” by the 11th Annual World ADC Awards.  The World ADC Awards were created 11 years ago to commemorate scientific excellence within ADC research. A panel of expert judges will determine the winner and runner-up from eight shortlisted candidates. The results will be announced at the World ADC Conference in San Diego, California, on Wednesday, November 6, 2024.